Figure 4.
Platelet-associated TGF-β1 enhanced immunosuppressive functions of MDSCs in active-ITP mice. (A) The dot plots of MDSC enriched populations for cell therapy. (B) Platelet counts among the control, control-MDSC, Romi-MDSC, and Romi + TGF-βi–MDSC groups differed significantly on day 28. Immune cells from all the groups were isolated and detected. (C) Representative flow-cytometric plots of cell cycle for CD4+ cells (G0 stage: Hoechst 33342– Ki-67–; G1 stage: Hoechst 33342– Ki-67+; S-G2/M stage: Hoechst 33342+ Ki-67+). Percentage of Th1 (D), Th2 (E), Th17 (F), and Tregs (G) in CD4+ cells. Percentage of FasL+ (H), granzyme B+ (I), and perforin+ CTLs (J). Percentage of GL-7+ B cells (K), CD138+ B cells (L), plasmablasts (M), and plasma cells (N). (O) The level of serum anti-CD61.

Platelet-associated TGF-β1 enhanced immunosuppressive functions of MDSCs in active-ITP mice. (A) The dot plots of MDSC enriched populations for cell therapy. (B) Platelet counts among the control, control-MDSC, Romi-MDSC, and Romi + TGF-βi–MDSC groups differed significantly on day 28. Immune cells from all the groups were isolated and detected. (C) Representative flow-cytometric plots of cell cycle for CD4+ cells (G0 stage: Hoechst 33342– Ki-67–; G1 stage: Hoechst 33342– Ki-67+; S-G2/M stage: Hoechst 33342+ Ki-67+). Percentage of Th1 (D), Th2 (E), Th17 (F), and Tregs (G) in CD4+ cells. Percentage of FasL+ (H), granzyme B+ (I), and perforin+ CTLs (J). Percentage of GL-7+ B cells (K), CD138+ B cells (L), plasmablasts (M), and plasma cells (N). (O) The level of serum anti-CD61.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal